Vote for your favorite mineral in #MinCup25! - Paddlewheelite vs. Mannardite
It's a battle of the tiny as bright green #paddlewheelite goes up against jet black #mannardite. Both are small yet mighty minerals, but only one can win!
Log InRegister
Quick Links : The Mindat ManualThe Rock H. Currier Digital LibraryMindat Newsletter [Free Download]
Home PageAbout MindatThe Mindat ManualHistory of MindatCopyright StatusWho We AreContact UsAdvertise on Mindat
Donate to MindatCorporate SponsorshipSponsor a PageSponsored PagesMindat AdvertisersAdvertise on Mindat
Learning CenterWhat is a mineral?The most common minerals on earthInformation for EducatorsMindat ArticlesThe ElementsThe Rock H. Currier Digital LibraryGeologic Time
Minerals by PropertiesMinerals by ChemistryAdvanced Locality SearchRandom MineralRandom LocalitySearch by minIDLocalities Near MeSearch ArticlesSearch GlossaryMore Search Options
Search For:
Mineral Name:
Locality Name:
Keyword(s):
 
The Mindat ManualAdd a New PhotoRate PhotosLocality Edit ReportCoordinate Completion ReportAdd Glossary Item
Mining CompaniesStatisticsUsersMineral MuseumsClubs & OrganizationsMineral Shows & EventsThe Mindat DirectoryDevice SettingsThe Mineral Quiz
Photo SearchPhoto GalleriesSearch by ColorNew Photos TodayNew Photos YesterdayMembers' Photo GalleriesPast Photo of the Day GalleryPhotography

(2018, August) Reactions Weekly Vol. 1713 (1) Springer Science and Business Media LLC

Advanced
   -   Only viewable:
Reference TypeJournal (issue)
JournalReactions Weekly
Year2018 (August)Volume1713
Issue1
PublisherSpringer Science and Business Media LLC
Mindat Ref. ID13371305Long-form Identifiermindat:1:5:13371305:5
GUID0
Full Reference(2018, August) Reactions Weekly Vol. 1713 (1) Springer Science and Business Media LLC
Plain Text(2018, August) Reactions Weekly Vol. 1713 (1) Springer Science and Business Media LLC
In(2018) Reactions Weekly Vol. 1713. Springer Science and Business Media LLC

Contains

1 2
Page 1 of 2		Next Page
(2018) Health Canada: risk of acute pancreatitis with SGLT2 inhibitors. Reactions Weekly, 1713 (1) 1 doi:10.1007/s40278-018-49835-9
(2018) Infliximab linked with risk of blistering skin condition. Reactions Weekly, 1713 (1) 2 doi:10.1007/s40278-018-49836-9
(2018) Strengthened diabetic ketoacidosis warning for SGLT2 inhibitors. Reactions Weekly, 1713 (1) 3 doi:10.1007/s40278-018-49837-9
(2018) US FDA takes key actions for bulk drugs used for compounding. Reactions Weekly, 1713 (1) 4 doi:10.1007/s40278-018-49838-9
(2018) Faulty rabies and DTaP vaccines in China. Reactions Weekly, 1713 (1) 5 doi:10.1007/s40278-018-49839-9
(2018) Acute cardiovascular events in transgender patients. Reactions Weekly, 1713 (1) 6 doi:10.1007/s40278-018-49840-8
(2018) Adverse events with second-line sulfonylureas. Reactions Weekly, 1713 (1) 7 doi:10.1007/s40278-018-49841-8
(2018) Children frequently prescribed opioids as outpatients in US. Reactions Weekly, 1713 (1) 8 doi:10.1007/s40278-018-49842-8
(2018) Epinephrine for out-of-hospital cardiac arrest has neurological risk. Reactions Weekly, 1713 (1) 9 doi:10.1007/s40278-018-49843-8
(2018) Increased HCC risk in cirrhosis patients treated with DAAs?. Reactions Weekly, 1713 (1) 10 doi:10.1007/s40278-018-49844-8
(2018) Monitoring of testosterone prescribing in the USA. Reactions Weekly, 1713 (1) 11 doi:10.1007/s40278-018-49845-8
(2018) Recurrent serious infection following biologic therapy. Reactions Weekly, 1713 (1) 12 doi:10.1007/s40278-018-49846-8
(2018) Safe use of zolpidem is uncommon in the US. Reactions Weekly, 1713 (1) 13 doi:10.1007/s40278-018-49847-8
(2018) Sildenafil for fetal growth restriction: fatal lung disorders. Reactions Weekly, 1713 (1) 14 doi:10.1007/s40278-018-49848-8
(2018) Abiraterone/leuprorelin/risedronic acid. Reactions Weekly, 1713 (1) 15 doi:10.1007/s40278-018-49849-8
(2018) Acetylcysteine/paracetamol overdose. Reactions Weekly, 1713 (1) 16 doi:10.1007/s40278-018-49850-7
(2018) Adalimumab/infliximab. Reactions Weekly, 1713 (1) 17 doi:10.1007/s40278-018-49851-7
(2018) Alemtuzumab. Reactions Weekly, 1713 (1) 18 doi:10.1007/s40278-018-49852-7
(2018) Alirocumab. Reactions Weekly, 1713 (1) 19 doi:10.1007/s40278-018-49853-7
(2018) Allopurinol. Reactions Weekly, 1713 (1) 20 doi:10.1007/s40278-018-49854-7
(2018) Allopurinol/azathioprine/mercaptopurine. Reactions Weekly, 1713 (1) 21 doi:10.1007/s40278-018-49855-7
(2018) Alteplase overdose. Reactions Weekly, 1713 (1) 22 doi:10.1007/s40278-018-49856-7
(2018) Amantadine/fingolimod. Reactions Weekly, 1713 (1) 23 doi:10.1007/s40278-018-49857-7
(2018) Amitriptyline overdose. Reactions Weekly, 1713 (1) 24 doi:10.1007/s40278-018-49858-7
(2018) Amlodipine/metoprolol interaction/overdose. Reactions Weekly, 1713 (1) 25 doi:10.1007/s40278-018-49859-7
(2018) Amoxicillin. Reactions Weekly, 1713 (1) 26 doi:10.1007/s40278-018-49860-6
(2018) Amoxicillin/clavulanic-acid/lormetazepam. Reactions Weekly, 1713 (1) 27 doi:10.1007/s40278-018-49861-6
(2018) Amphotericin-B-liposomal. Reactions Weekly, 1713 (1) 28 doi:10.1007/s40278-018-49862-6
(2018) Amphotericin-B/amphotericin-B-liposomal/fluconazole. Reactions Weekly, 1713 (1) 29 doi:10.1007/s40278-018-49863-6
(2018) Antibacterial/succimer. Reactions Weekly, 1713 (1) 30 doi:10.1007/s40278-018-49864-6
(2018) Antibacterials/vitamins/warfarin. Reactions Weekly, 1713 (1) 31 doi:10.1007/s40278-018-49865-6
(2018) Antibiotics. Reactions Weekly, 1713 (1) 32 doi:10.1007/s40278-018-49866-6
(2018) Antiepileptic drugs/anaesthetics. Reactions Weekly, 1713 (1) 33 doi:10.1007/s40278-018-49867-6
(2018) Antineoplastics. Reactions Weekly, 1713 (1) 34 doi:10.1007/s40278-018-49868-6
(2018) Antineoplastics. Reactions Weekly, 1713 (1) 35 doi:10.1007/s40278-018-49869-6
(2018) Antineoplastics. Reactions Weekly, 1713 (1) 36 doi:10.1007/s40278-018-49870-5
(2018) Antineoplastics. Reactions Weekly, 1713 (1) 37 doi:10.1007/s40278-018-49871-5
(2018) Antineoplastics. Reactions Weekly, 1713 (1) 38 doi:10.1007/s40278-018-49872-5
(2018) Antineoplastics. Reactions Weekly, 1713 (1) 39 doi:10.1007/s40278-018-49873-5
(2018) Antineoplastics. Reactions Weekly, 1713 (1) 40 doi:10.1007/s40278-018-49874-5
(2018) Antineoplastics. Reactions Weekly, 1713 (1) 41 doi:10.1007/s40278-018-49875-5
(2018) Antineoplastics/etoposide/immune globulin. Reactions Weekly, 1713 (1) 42 doi:10.1007/s40278-018-49876-5
(2018) Antineoplastics/folinic-acid. Reactions Weekly, 1713 (1) 43 doi:10.1007/s40278-018-49877-5
(2018) Antineoplastics/folinic-acid. Reactions Weekly, 1713 (1) 44 doi:10.1007/s40278-018-49878-5
(2018) Antiretroviral/antiplatelet interaction. Reactions Weekly, 1713 (1) 45 doi:10.1007/s40278-018-49879-5
(2018) Aripiprazole/benzatropine. Reactions Weekly, 1713 (1) 46 doi:10.1007/s40278-018-49880-4
(2018) Aripiprazole/sertraline/trazodone. Reactions Weekly, 1713 (1) 47 doi:10.1007/s40278-018-49881-4
(2018) Aspirin. Reactions Weekly, 1713 (1) 48 doi:10.1007/s40278-018-49882-4
(2018) Aspirin. Reactions Weekly, 1713 (1) 49 doi:10.1007/s40278-018-49883-4
(2018) Aspirin/clopidogrel/coumarin. Reactions Weekly, 1713 (1) 50 doi:10.1007/s40278-018-49884-4
(2018) Atazanavir/ritonavir/tacrolimus interaction. Reactions Weekly, 1713 (1) 51 doi:10.1007/s40278-018-49885-4
(2018) Atracurium besilate/povidone iodine. Reactions Weekly, 1713 (1) 52 doi:10.1007/s40278-018-49886-4
(2018) Azacitidine. Reactions Weekly, 1713 (1) 53 doi:10.1007/s40278-018-49887-4
(2018) Azathioprine/ciclosporin/prednisolone. Reactions Weekly, 1713 (1) 54 doi:10.1007/s40278-018-49888-4
(2018) Azithromycin. Reactions Weekly, 1713 (1) 55 doi:10.1007/s40278-018-49889-4
(2018) Azithromycin. Reactions Weekly, 1713 (1) 56 doi:10.1007/s40278-018-49890-3
(2018) Azithromycin/clarithromycin/erythromycin. Reactions Weekly, 1713 (1) 57 doi:10.1007/s40278-018-49891-3
(2018) Baclofen overdose. Reactions Weekly, 1713 (1) 58 doi:10.1007/s40278-018-49892-3
(2018) BCG. Reactions Weekly, 1713 (1) 59 doi:10.1007/s40278-018-49893-3
(2018) BCG. Reactions Weekly, 1713 (1) 60 doi:10.1007/s40278-018-49894-3
(2018) Bedaquiline/linezolid. Reactions Weekly, 1713 (1) 61 doi:10.1007/s40278-018-49895-3
(2018) Benzobarbital/pregabalin. Reactions Weekly, 1713 (1) 62 doi:10.1007/s40278-018-49896-3
(2018) Bevacizumab. Reactions Weekly, 1713 (1) 63 doi:10.1007/s40278-018-49897-3
(2018) Bevacizumab/dexamethasone. Reactions Weekly, 1713 (1) 64 doi:10.1007/s40278-018-49898-3
(2018) Bevacizumab/tipiracil/trifluridine. Reactions Weekly, 1713 (1) 65 doi:10.1007/s40278-018-49899-3
(2018) Botulinum-toxin-A. Reactions Weekly, 1713 (1) 66 doi:10.1007/s40278-018-49900-x
(2018) Bucillamine. Reactions Weekly, 1713 (1) 67 doi:10.1007/s40278-018-49901-x
(2018) Bupivacaine/lidocaine. Reactions Weekly, 1713 (1) 68 doi:10.1007/s40278-018-49902-x
(2018) Buprenorphine/naloxone/gabapentin abuse/interaction. Reactions Weekly, 1713 (1) 69 doi:10.1007/s40278-018-49903-x
(2018) Cabergoline. Reactions Weekly, 1713 (1) 70 doi:10.1007/s40278-018-49904-x
(2018) Caesium-131. Reactions Weekly, 1713 (1) 71 doi:10.1007/s40278-018-49905-x
(2018) Camrelizumab. Reactions Weekly, 1713 (1) 72 doi:10.1007/s40278-018-49906-x
(2018) Canagliflozin/empagliflozin. Reactions Weekly, 1713 (1) 73 doi:10.1007/s40278-018-49907-x
(2018) Canakinumab. Reactions Weekly, 1713 (1) 74 doi:10.1007/s40278-018-49908-x
(2018) Capecitabine/oxaliplatin. Reactions Weekly, 1713 (1) 75 doi:10.1007/s40278-018-49909-x
(2018) Captopril. Reactions Weekly, 1713 (1) 76 doi:10.1007/s40278-018-49910-9
(2018) Carbamazepine. Reactions Weekly, 1713 (1) 77 doi:10.1007/s40278-018-49911-9
(2018) Carbamazepine/phenobarbital. Reactions Weekly, 1713 (1) 78 doi:10.1007/s40278-018-49912-9
(2018) Carbimazole. Reactions Weekly, 1713 (1) 79 doi:10.1007/s40278-018-49913-9
(2018) Carboplatin/epirubicin. Reactions Weekly, 1713 (1) 80 doi:10.1007/s40278-018-49914-9
(2018) Carboplatin/gefitinib/paclitaxel. Reactions Weekly, 1713 (1) 81 doi:10.1007/s40278-018-49915-9
(2018) Carboplatin/paclitaxel. Reactions Weekly, 1713 (1) 82 doi:10.1007/s40278-018-49916-9
(2018) Cefoperazone/rivaroxaban. Reactions Weekly, 1713 (1) 83 doi:10.1007/s40278-018-49917-9
(2018) Celecoxib/pregabalin. Reactions Weekly, 1713 (1) 84 doi:10.1007/s40278-018-49918-9
(2018) Cetirizine. Reactions Weekly, 1713 (1) 85 doi:10.1007/s40278-018-49919-9
(2018) Cetuximab. Reactions Weekly, 1713 (1) 86 doi:10.1007/s40278-018-49920-8
(2018) Chloroquine. Reactions Weekly, 1713 (1) 87 doi:10.1007/s40278-018-49921-8
(2018) Ciclosporin/colchicine/simvastatin interaction. Reactions Weekly, 1713 (1) 88 doi:10.1007/s40278-018-49922-8
(2018) Ciclosporin/methylprednisolone. Reactions Weekly, 1713 (1) 89 doi:10.1007/s40278-018-49923-8
(2018) Ciclosporin/methylprednisolone. Reactions Weekly, 1713 (1) 90 doi:10.1007/s40278-018-49924-8
(2018) Ciclosporin/olanzapine interactions. Reactions Weekly, 1713 (1) 91 doi:10.1007/s40278-018-49925-8
(2018) Cilostazol/clopidogrel/warfarin. Reactions Weekly, 1713 (1) 92 doi:10.1007/s40278-018-49926-8
(2018) Cisplatin. Reactions Weekly, 1713 (1) 93 doi:10.1007/s40278-018-49927-8
(2018) Cisplatin/doxorubicin. Reactions Weekly, 1713 (1) 94 doi:10.1007/s40278-018-49928-8
(2018) Cisplatin/etoposide/paclitaxel. Reactions Weekly, 1713 (1) 95 doi:10.1007/s40278-018-49929-8
(2018) Clobazam/stiripentol. Reactions Weekly, 1713 (1) 96 doi:10.1007/s40278-018-49930-7
(2018) Clonazepam. Reactions Weekly, 1713 (1) 97 doi:10.1007/s40278-018-49931-7
(2018) Clonazepam/vortioxetine overdose. Reactions Weekly, 1713 (1) 98 doi:10.1007/s40278-018-49932-7
(2018) Clozapine. Reactions Weekly, 1713 (1) 99 doi:10.1007/s40278-018-49933-7
(2018) Clozapine withdrawal. Reactions Weekly, 1713 (1) 100 doi:10.1007/s40278-018-49934-7
(2018) Clozapine/mirabegron interaction. Reactions Weekly, 1713 (1) 101 doi:10.1007/s40278-018-49935-7
(2018) Codeine/fentanyl/paracetamol. Reactions Weekly, 1713 (1) 102 doi:10.1007/s40278-018-49936-7
(2018) Codeine/glucocorticoids. Reactions Weekly, 1713 (1) 103 doi:10.1007/s40278-018-49937-7
(2018) Colchicine overdose. Reactions Weekly, 1713 (1) 104 doi:10.1007/s40278-018-49938-7
(2018) Colistin. Reactions Weekly, 1713 (1) 105 doi:10.1007/s40278-018-49939-7
(2018) Colistin/meropenem/tigecycline. Reactions Weekly, 1713 (1) 106 doi:10.1007/s40278-018-49940-6
(2018) Colistin/polymixin-B interaction. Reactions Weekly, 1713 (1) 107 doi:10.1007/s40278-018-49941-6
(2018) Corticosteroids/fluoxetine. Reactions Weekly, 1713 (1) 108 doi:10.1007/s40278-018-49942-6
(2018) Cortisone/epinephrine. Reactions Weekly, 1713 (1) 109 doi:10.1007/s40278-018-49943-6
(2018) Cotrimoxazole. Reactions Weekly, 1713 (1) 110 doi:10.1007/s40278-018-49944-6
(2018) Cotrimoxazole. Reactions Weekly, 1713 (1) 111 doi:10.1007/s40278-018-49945-6
(2018) Cotrimoxazole. Reactions Weekly, 1713 (1) 112 doi:10.1007/s40278-018-49946-6
(2018) Cyclophosphamide. Reactions Weekly, 1713 (1) 113 doi:10.1007/s40278-018-49947-6
(2018) Cyclophosphamide/prednisone. Reactions Weekly, 1713 (1) 114 doi:10.1007/s40278-018-49948-6
(2018) Dabigatran etexilate. Reactions Weekly, 1713 (1) 115 doi:10.1007/s40278-018-49949-6
(2018) Dabigatran etexilate. Reactions Weekly, 1713 (1) 116 doi:10.1007/s40278-018-49950-5
(2018) Dabigatran etexilate. Reactions Weekly, 1713 (1) 117 doi:10.1007/s40278-018-49951-5
(2018) Dabrafenib/trametinib. Reactions Weekly, 1713 (1) 118 doi:10.1007/s40278-018-49952-5
(2018) Dabrafenib/trametinib. Reactions Weekly, 1713 (1) 119 doi:10.1007/s40278-018-49953-5
(2018) Daclatasvir/sofosbuvir. Reactions Weekly, 1713 (1) 120 doi:10.1007/s40278-018-49954-5
(2018) Daclatasvir/sofosbuvir. Reactions Weekly, 1713 (1) 121 doi:10.1007/s40278-018-49955-5
(2018) Danazol. Reactions Weekly, 1713 (1) 122 doi:10.1007/s40278-018-49956-5
(2018) Daptomycin. Reactions Weekly, 1713 (1) 123 doi:10.1007/s40278-018-49957-5
(2018) Dasatinib/imatinib. Reactions Weekly, 1713 (1) 124 doi:10.1007/s40278-018-49958-5
(2018) Deferasirox. Reactions Weekly, 1713 (1) 125 doi:10.1007/s40278-018-49959-5
(2018) Deferiprone. Reactions Weekly, 1713 (1) 126 doi:10.1007/s40278-018-49960-4
(2018) Denosumab. Reactions Weekly, 1713 (1) 127 doi:10.1007/s40278-018-49961-4
(2018) Denosumab Withdrawal. Reactions Weekly, 1713 (1) 128 doi:10.1007/s40278-018-49962-4
(2018) Desvenlafaxine/duloxetine/temazepam overdose. Reactions Weekly, 1713 (1) 129 doi:10.1007/s40278-018-49963-4
(2018) Dexamethasone/digoxin/sotalol. Reactions Weekly, 1713 (1) 130 doi:10.1007/s40278-018-49964-4
(2018) Dexamethasone/muscle relaxants. Reactions Weekly, 1713 (1) 131 doi:10.1007/s40278-018-49965-4
(2018) Dexamethasone/prednisone. Reactions Weekly, 1713 (1) 132 doi:10.1007/s40278-018-49966-4
(2018) Dexmedetomidine. Reactions Weekly, 1713 (1) 133 doi:10.1007/s40278-018-49967-4
(2018) Dextromethorphan abuse/overdose. Reactions Weekly, 1713 (1) 134 doi:10.1007/s40278-018-49968-4
(2018) Dibotermin-α. Reactions Weekly, 1713 (1) 135 doi:10.1007/s40278-018-49969-4
(2018) Diclofenac. Reactions Weekly, 1713 (1) 136 doi:10.1007/s40278-018-49970-3
(2018) Dimethyl fumarate. Reactions Weekly, 1713 (1) 137 doi:10.1007/s40278-018-49971-3
(2018) Docetaxel. Reactions Weekly, 1713 (1) 138 doi:10.1007/s40278-018-49972-3
(2018) Domperidone withdrawal. Reactions Weekly, 1713 (1) 139 doi:10.1007/s40278-018-49973-3
(2018) Donepezil/rivastigmine. Reactions Weekly, 1713 (1) 140 doi:10.1007/s40278-018-49974-3
(2018) Dronedarone/β-adrenergic receptor antagonists. Reactions Weekly, 1713 (1) 141 doi:10.1007/s40278-018-49975-3
(2018) Eculizumab. Reactions Weekly, 1713 (1) 142 doi:10.1007/s40278-018-49976-3
(2018) Eculizumab. Reactions Weekly, 1713 (1) 143 doi:10.1007/s40278-018-49977-3
(2018) Eltrombopag. Reactions Weekly, 1713 (1) 144 doi:10.1007/s40278-018-49978-3
(2018) Empagliflozin. Reactions Weekly, 1713 (1) 145 doi:10.1007/s40278-018-49979-3
(2018) Enoxaparin sodium/prednisone. Reactions Weekly, 1713 (1) 146 doi:10.1007/s40278-018-49980-2
(2018) Epirubicin. Reactions Weekly, 1713 (1) 147 doi:10.1007/s40278-018-49981-2
(2018) Erlotinib. Reactions Weekly, 1713 (1) 148 doi:10.1007/s40278-018-49982-2
(2018) Erlotinib. Reactions Weekly, 1713 (1) 149 doi:10.1007/s40278-018-49983-2
(2018) Eslicarbazepine acetate. Reactions Weekly, 1713 (1) 150 doi:10.1007/s40278-018-49984-2
(2018) Esomeprazole/omeprazole/pantoprazole. Reactions Weekly, 1713 (1) 151 doi:10.1007/s40278-018-49985-2
(2018) Etanercept. Reactions Weekly, 1713 (1) 152 doi:10.1007/s40278-018-49986-2
(2018) Etanercept. Reactions Weekly, 1713 (1) 153 doi:10.1007/s40278-018-49987-2
(2018) Etanercept/sulfasalazine. Reactions Weekly, 1713 (1) 154 doi:10.1007/s40278-018-49988-2
(2018) Ethinylestradiol/etonogestrel. Reactions Weekly, 1713 (1) 155 doi:10.1007/s40278-018-49989-2
(2018) Ethylene glycol/Metoprolol. Reactions Weekly, 1713 (1) 156 doi:10.1007/s40278-018-49990-1
(2018) Everolimus. Reactions Weekly, 1713 (1) 157 doi:10.1007/s40278-018-49991-1
(2018) Everolimus. Reactions Weekly, 1713 (1) 158 doi:10.1007/s40278-018-49992-1
(2018) Exemestane/trastuzumab. Reactions Weekly, 1713 (1) 159 doi:10.1007/s40278-018-49993-1
(2018) Fentanyl abuse. Reactions Weekly, 1713 (1) 160 doi:10.1007/s40278-018-49994-1
(2018) Fentanyl/ketamine/propofol. Reactions Weekly, 1713 (1) 161 doi:10.1007/s40278-018-49995-1
(2018) Fentanyl/nefopam interaction. Reactions Weekly, 1713 (1) 162 doi:10.1007/s40278-018-49996-1
(2018) Fentanyl/U-47700 overdose. Reactions Weekly, 1713 (1) 163 doi:10.1007/s40278-018-49997-1
(2018) Ferrous sulfate. Reactions Weekly, 1713 (1) 164 doi:10.1007/s40278-018-49998-1
(2018) Ferrous-sulfate misuse. Reactions Weekly, 1713 (1) 165 doi:10.1007/s40278-018-49999-1
(2018) Fluconazole. Reactions Weekly, 1713 (1) 166 doi:10.1007/s40278-018-50000-z
(2018) Fluindione overdose/nebivolol. Reactions Weekly, 1713 (1) 167 doi:10.1007/s40278-018-50001-z
(2018) Fluoxetine. Reactions Weekly, 1713 (1) 168 doi:10.1007/s40278-018-50002-z
(2018) Fluticasone furoate. Reactions Weekly, 1713 (1) 169 doi:10.1007/s40278-018-50003-z
(2018) Fluticasone propionate. Reactions Weekly, 1713 (1) 170 doi:10.1007/s40278-018-50004-z
(2018) Folinic acid/oxaliplatin/palonosetron. Reactions Weekly, 1713 (1) 171 doi:10.1007/s40278-018-50005-z
(2018) Foscarnet/ganciclovir/valganciclovir. Reactions Weekly, 1713 (1) 172 doi:10.1007/s40278-018-50006-z
(2018) Furosemide/pregabalin. Reactions Weekly, 1713 (1) 173 doi:10.1007/s40278-018-50007-z
(2018) Gabapentin overdose. Reactions Weekly, 1713 (1) 174 doi:10.1007/s40278-018-50008-z
(2018) Gabapentin/triamcinolone. Reactions Weekly, 1713 (1) 175 doi:10.1007/s40278-018-50009-z
(2018) Gefitinib. Reactions Weekly, 1713 (1) 176 doi:10.1007/s40278-018-50010-y
(2018) Gefitinib/osimertinib. Reactions Weekly, 1713 (1) 177 doi:10.1007/s40278-018-50011-y
(2018) Gemcitabine/oxaliplatin/pegaspargase. Reactions Weekly, 1713 (1) 178 doi:10.1007/s40278-018-50012-y
(2018) Gimeracil/oteracil/tegafur. Reactions Weekly, 1713 (1) 179 doi:10.1007/s40278-018-50013-y
(2018) Gimeracil/oteracil/tegafur/rivoceranib. Reactions Weekly, 1713 (1) 180 doi:10.1007/s40278-018-50014-y
(2018) Glucagon/somatostatin. Reactions Weekly, 1713 (1) 181 doi:10.1007/s40278-018-50015-y
(2018) Glucose. Reactions Weekly, 1713 (1) 182 doi:10.1007/s40278-018-50016-y
(2018) Glucose. Reactions Weekly, 1713 (1) 183 doi:10.1007/s40278-018-50017-y
(2018) Griseofulvin. Reactions Weekly, 1713 (1) 184 doi:10.1007/s40278-018-50018-y
(2018) Heparin. Reactions Weekly, 1713 (1) 185 doi:10.1007/s40278-018-50019-y
(2018) Heparin. Reactions Weekly, 1713 (1) 186 doi:10.1007/s40278-018-50020-x
(2018) Heparin. Reactions Weekly, 1713 (1) 187 doi:10.1007/s40278-018-50021-x
(2018) Heparin. Reactions Weekly, 1713 (1) 188 doi:10.1007/s40278-018-50022-x
(2018) Heparin/monteplase. Reactions Weekly, 1713 (1) 189 doi:10.1007/s40278-018-50023-x
(2018) Human-papillomavirus-vaccine-recombinant-bivalent-japan-vaccine/medimmune. Reactions Weekly, 1713 (1) 190 doi:10.1007/s40278-018-50024-x
(2018) Hydroxychloroquine overdose. Reactions Weekly, 1713 (1) 191 doi:10.1007/s40278-018-50025-x
(2018) Ibrutinib Withdrawal. Reactions Weekly, 1713 (1) 192 doi:10.1007/s40278-018-50026-x
(2018) Immunosuppresants. Reactions Weekly, 1713 (1) 193 doi:10.1007/s40278-018-50027-x
(2018) Immunosuppressants. Reactions Weekly, 1713 (1) 194 doi:10.1007/s40278-018-50028-x
(2018) Immunosuppressants. Reactions Weekly, 1713 (1) 195 doi:10.1007/s40278-018-50029-x
(2018) Immunosuppressants. Reactions Weekly, 1713 (1) 196 doi:10.1007/s40278-018-50030-9
(2018) Insulin degludec overdose. Reactions Weekly, 1713 (1) 197 doi:10.1007/s40278-018-50031-9
(2018) Insulin-glargine/insulin-suspension-isophane/insulin. Reactions Weekly, 1713 (1) 198 doi:10.1007/s40278-018-50032-9
(2018) Insulin/sodium chloride. Reactions Weekly, 1713 (1) 199 doi:10.1007/s40278-018-50033-9
(2018) Interferon β-1b. Reactions Weekly, 1713 (1) 200 doi:10.1007/s40278-018-50034-9
(2018) Ipilimumab/nivolumab. Reactions Weekly, 1713 (1) 201 doi:10.1007/s40278-018-50035-9
(2018) Ipilimumab/nivolumab. Reactions Weekly, 1713 (1) 202 doi:10.1007/s40278-018-50036-9
(2018) Ipilimumab/nivolumab. Reactions Weekly, 1713 (1) 203 doi:10.1007/s40278-018-50037-9
(2018) Ipilimumab/nivolumab/pembrolizumab. Reactions Weekly, 1713 (1) 204 doi:10.1007/s40278-018-50038-9
(2018) Ipilimumab/nivolumab/pembrolizumab. Reactions Weekly, 1713 (1) 205 doi:10.1007/s40278-018-50039-9
(2018) Iron sucrose overdose. Reactions Weekly, 1713 (1) 206 doi:10.1007/s40278-018-50040-8
(2018) Isoniazid. Reactions Weekly, 1713 (1) 207 doi:10.1007/s40278-018-50041-8
(2018) Isopropyl alcohol overdose. Reactions Weekly, 1713 (1) 208 doi:10.1007/s40278-018-50042-8
(2018) Ketamine/midazolam/propofol interaction. Reactions Weekly, 1713 (1) 209 doi:10.1007/s40278-018-50043-8
(2018) Lacosamide overdose. Reactions Weekly, 1713 (1) 210 doi:10.1007/s40278-018-50044-8
(2018) Lacosamide/perampanel. Reactions Weekly, 1713 (1) 211 doi:10.1007/s40278-018-50045-8
(2018) Lamotrigine/paroxetine/quetiapine. Reactions Weekly, 1713 (1) 212 doi:10.1007/s40278-018-50046-8
(2018) Ledipasvir/sofosbuvir. Reactions Weekly, 1713 (1) 213 doi:10.1007/s40278-018-50047-8
(2018) Lenalidomide. Reactions Weekly, 1713 (1) 214 doi:10.1007/s40278-018-50048-8
(2018) Lenalidomide. Reactions Weekly, 1713 (1) 215 doi:10.1007/s40278-018-50049-8
(2018) Levodopa/benserazide/carbidopa/Mucuna pruriens. Reactions Weekly, 1713 (1) 216 doi:10.1007/s40278-018-50050-7
(2018) Levodopa/carbidopa/ropinirole. Reactions Weekly, 1713 (1) 217 doi:10.1007/s40278-018-50051-7
(2018) Levothyroxine sodium/sevelamer interaction. Reactions Weekly, 1713 (1) 218 doi:10.1007/s40278-018-50052-7
(2018) Lidocaine. Reactions Weekly, 1713 (1) 219 doi:10.1007/s40278-018-50053-7
(2018) Linagliptin/sitagliptin. Reactions Weekly, 1713 (1) 220 doi:10.1007/s40278-018-50054-7
(2018) Linezolid/vancomycin. Reactions Weekly, 1713 (1) 221 doi:10.1007/s40278-018-50055-7
(2018) Lipid emulsion/sodium bicarbonate. Reactions Weekly, 1713 (1) 222 doi:10.1007/s40278-018-50056-7
(2018) Lithium/olanzapine withdrawal. Reactions Weekly, 1713 (1) 223 doi:10.1007/s40278-018-50057-7
(2018) Lomitapide. Reactions Weekly, 1713 (1) 224 doi:10.1007/s40278-018-50058-7
(2018) Loperamide misuse. Reactions Weekly, 1713 (1) 225 doi:10.1007/s40278-018-50059-7
(2018) Lurasidone. Reactions Weekly, 1713 (1) 226 doi:10.1007/s40278-018-50060-6
(2018) Lurasidone. Reactions Weekly, 1713 (1) 227 doi:10.1007/s40278-018-50061-6
(2018) Matricaria chamomilla/melatonin/valerian root. Reactions Weekly, 1713 (1) 228 doi:10.1007/s40278-018-50062-6
(2018) Mesalazine. Reactions Weekly, 1713 (1) 229 doi:10.1007/s40278-018-50063-6
(2018) Mesalazine. Reactions Weekly, 1713 (1) 230 doi:10.1007/s40278-018-50064-6
(2018) Metamfetamine/sodium-oxybate. Reactions Weekly, 1713 (1) 231 doi:10.1007/s40278-018-50065-6
(2018) Metformin. Reactions Weekly, 1713 (1) 232 doi:10.1007/s40278-018-50066-6
(2018) Metformin. Reactions Weekly, 1713 (1) 233 doi:10.1007/s40278-018-50067-6
(2018) Metformin. Reactions Weekly, 1713 (1) 234 doi:10.1007/s40278-018-50068-6
(2018) Metformin. Reactions Weekly, 1713 (1) 235 doi:10.1007/s40278-018-50069-6
(2018) Methotrexate Overdose. Reactions Weekly, 1713 (1) 236 doi:10.1007/s40278-018-50070-5
(2018) Methotrexate/ruxolitinib interaction. Reactions Weekly, 1713 (1) 237 doi:10.1007/s40278-018-50071-5
(2018) Methylprednisolone. Reactions Weekly, 1713 (1) 238 doi:10.1007/s40278-018-50072-5
(2018) Methylprednisolone. Reactions Weekly, 1713 (1) 239 doi:10.1007/s40278-018-50073-5
(2018) Metronidazole. Reactions Weekly, 1713 (1) 240 doi:10.1007/s40278-018-50074-5
(2018) Mexiletine. Reactions Weekly, 1713 (1) 241 doi:10.1007/s40278-018-50075-5
(2018) Midazolam/propofol. Reactions Weekly, 1713 (1) 242 doi:10.1007/s40278-018-50076-5
(2018) Miglitol. Reactions Weekly, 1713 (1) 243 doi:10.1007/s40278-018-50077-5
(2018) Minoxidil. Reactions Weekly, 1713 (1) 244 doi:10.1007/s40278-018-50078-5
(2018) Misoprostol. Reactions Weekly, 1713 (1) 245 doi:10.1007/s40278-018-50079-5
(2018) Mitomycin. Reactions Weekly, 1713 (1) 246 doi:10.1007/s40278-018-50080-4
(2018) Morphine. Reactions Weekly, 1713 (1) 247 doi:10.1007/s40278-018-50081-4
(2018) Multiple drug abuse. Reactions Weekly, 1713 (1) 248 doi:10.1007/s40278-018-50082-4
(2018) Multiple drug overdose. Reactions Weekly, 1713 (1) 249 doi:10.1007/s40278-018-50083-4
(2018) Multiple drugs. Reactions Weekly, 1713 (1) 250 doi:10.1007/s40278-018-50084-4
1 2
Page 1 of 2		Next Page

See Also

These are possibly similar items as determined by title/reference text matching only.

(2018, August) Reactions Weekly Vol. 1714 (1) Springer Science and Business Media LLC
(2018, August) Reactions Weekly Vol. 1715 (1) Springer Science and Business Media LLC
(2018, August) Reactions Weekly Vol. 1716 (1) Springer Science and Business Media LLC
(2016, August) Reactions Weekly Vol. 1613 (1) Springer Science and Business Media LLC
(2016, August) Reactions Weekly Vol. 1614 (1) Springer Science and Business Media LLC
(2016, August) Reactions Weekly Vol. 1615 (1) Springer Science and Business Media LLC
(2016, August) Reactions Weekly Vol. 1616 (1) Springer Science and Business Media LLC
(2013, August) Reactions Weekly Vol. 1463 (1) Springer Science and Business Media LLC
(2013, August) Reactions Weekly Vol. 1464 (1) Springer Science and Business Media LLC
(2013, August) Reactions Weekly Vol. 1465 (1) Springer Science and Business Media LLC
(2013, August) Reactions Weekly Vol. 1466 (1) Springer Science and Business Media LLC
 
and/or  
Mindat.org is an outreach project of the Hudson Institute of Mineralogy, a 501(c)(3) not-for-profit organization.
Copyright © mindat.org and the Hudson Institute of Mineralogy 1993-2025, except where stated. Most political location boundaries are © OpenStreetMap contributors. Mindat.org relies on the contributions of thousands of members and supporters. Founded in 2000 by Jolyon Ralph.
To cite: Ralph, J., Von Bargen, D., Martynov, P., Zhang, J., Que, X., Prabhu, A., Morrison, S. M., Li, W., Chen, W., & Ma, X. (2025). Mindat.org: The open access mineralogy database to accelerate data-intensive geoscience research. American Mineralogist, 110(6), 833–844. doi:10.2138/am-2024-9486.
Privacy Policy - Terms & Conditions - Contact Us / DMCA issues - Report a bug/vulnerability Current server date and time: September 16, 2025 15:11:50
Go to top of page